BioCentury
ARTICLE | Clinical News

DCR-MYC: Phase I ongoing

May 25, 2015 7:00 AM UTC

Dicerna said the open-label, dose-escalation, U.S. Phase I trial of IV DCR-MYC will now include an expansion cohort of patients with advanced pancreatic neuroendocrine tumors (PNETs). The addition is ...